Short answer: In tirzepatide vs retatrutide, the deciding difference is approval. Tirzepatide is FDA approved for weight management as Zepbound. Retatrutide is not FDA approved: it is an investigational drug still in clinical trials, so no clinic or pharmacy can legally sell it to you as a prescription medicine. Retatrutide produced larger average weight loss in its trials, but those trials compared it with placebo, not with tirzepatide.
By Alexandru Vieru. Independently researched. Last reviewed October 18, 2026. Educational information only, not medical advice. This page has no clinic recommendations or affiliate offers.
People searching tirzepatide vs retatrutide usually want to know two things: whether the newer drug works better, and whether they can get it. This page answers both from primary sources, the FDA label for Zepbound and the published retatrutide trials, and explains why a bigger number in one trial does not settle the comparison.
Tirzepatide vs retatrutide at a glance
| Tirzepatide (Zepbound) | Retatrutide | |
|---|---|---|
| FDA status | Approved for weight management and for obstructive sleep apnea with obesity | Not FDA approved; investigational |
| How it works | Acts on two hormone receptors, GIP and GLP-1 | Acts on three, GIP, GLP-1 and glucagon |
| How it is taken | Once-weekly injection | Once-weekly injection in trials |
| Main weight trial in adults without diabetes | 20.9% average loss at the highest dose over 72 weeks, against 3.1% on placebo | 25.0% average loss at the highest dose over 80 weeks, against 3.9% on placebo |
| Can you buy it legally? | Yes, with a prescription | No; only inside a clinical trial |
| Manufacturer price | From $299 a month self-pay through Lilly | None: it is not on sale |
Both drugs are made by Eli Lilly. The tirzepatide figures come from the Zepbound prescribing information on DailyMed, revised August 2026. The retatrutide figures come from the TRIUMPH-1 trial in the New England Journal of Medicine, published September 29, 2026.
Tirzepatide vs retatrutide: what is the difference?
Both medicines copy gut hormones that help regulate appetite and blood sugar. Tirzepatide activates two receptors: GIP and GLP-1. Retatrutide activates those two and adds a third, the glucagon receptor. Glucagon signaling is thought to increase the energy the body uses, which is one reason researchers expected larger weight loss. That is a hypothesis behind the drug's design, not something a reader should treat as a proven advantage.
The practical difference today is simpler. Tirzepatide has a full FDA label that sets out who it is for, how the dose is started and raised, what side effects to expect and who must not take it. Retatrutide has no label. Its doses, its long-term safety and the people it suits are still being worked out in trials.
Is retatrutide FDA approved?
No. Retatrutide is not FDA approved. It has not been approved for weight loss or for any other use, and no approved product containing it exists in the United States.
The FDA's page on unapproved GLP-1 drugs used for weight loss, read October 18, 2026, warns that retatrutide cannot be used in compounding under federal law. A product sold online as "retatrutide", whether labeled as compounded, as a research chemical or as a peptide "not for human use", is not a medicine the FDA has reviewed for safety, purity or dose.
Positive trial results do not change that status. A drug becomes available by prescription only after the FDA reviews the full application and approves a label. Until then, the only legitimate way to receive retatrutide is as a participant in a registered clinical trial.
Tirzepatide vs retatrutide weight loss in the trials
The headline numbers come from different trials, so read them side by side with care.
| Trial | Drug and dose | Length | Average weight change | Placebo |
|---|---|---|---|---|
| Zepbound Study 1, adults without diabetes | Tirzepatide 5 mg | 72 weeks | 15.0% loss | 3.1% loss |
| Zepbound Study 1 | Tirzepatide 10 mg | 72 weeks | 19.5% loss | 3.1% loss |
| Zepbound Study 1 | Tirzepatide 15 mg | 72 weeks | 20.9% loss | 3.1% loss |
| TRIUMPH-1, adults without diabetes | Retatrutide 4 mg | 80 weeks | 17.6% loss | 3.9% loss |
| TRIUMPH-1 | Retatrutide 9 mg | 80 weeks | 23.7% loss | 3.9% loss |
| TRIUMPH-1 | Retatrutide 12 mg | 80 weeks | 25.0% loss | 3.9% loss |
In adults with obesity and type 2 diabetes, the picture is similar but smaller for both. Zepbound's Study 2 reported 14.7% average loss at 15 mg after 72 weeks, against 3.2% on placebo. TRIUMPH-2 in The Lancet reported 18.8% at 12 mg of retatrutide after 80 weeks, against 5.1% on placebo.
Why these numbers are not a head-to-head result
- Different lengths. The retatrutide trials ran eight weeks longer, and weight usually keeps falling for months.
- Different people. Each trial enrolled its own volunteers, with different starting weights and health conditions.
- Different analysis. Each study chose its own way to handle people who stopped treatment early, which changes the averages.
- Placebo, not tirzepatide. Each drug was tested against a dummy injection. None of the trials cited here randomized people to tirzepatide versus retatrutide.
So the fair summary of tirzepatide vs retatrutide is that retatrutide's trial averages were larger than tirzepatide's, by a margin that a direct comparison would still need to confirm. An average also says little about one person: in every arm of these trials, some people lost far more than the average and some far less.
Tirzepatide vs retatrutide side effects
For both drugs, the most common problems are in the stomach and bowel, and they are most frequent while the dose is being increased.
Tirzepatide, from the Zepbound label: the common side effects are nausea, diarrhea, vomiting, constipation, abdominal pain, indigestion, injection site reactions, fatigue, allergic reactions, belching, hair loss and reflux. In the weight trials, 4.8%, 6.3% and 6.7% of people on 5, 10 and 15 mg stopped because of side effects, against 3.4% on placebo. The label carries a boxed warning about thyroid C-cell tumors seen in rodents and warns of pancreatitis, gallbladder disease and kidney injury from dehydration, among other risks.
Retatrutide, from the published trials: in TRIUMPH-2, diarrhea affected 34% of people on the 12 mg dose against 13% on placebo, and nausea 28% against 8%. Low blood pressure and dysesthesia, an abnormal or unpleasant skin sensation, were also more common than on placebo. Stopping treatment because of adverse events or death occurred in 12% on 9 mg and 8% on 12 mg, against 5% on placebo. The 2023 phase 2 trial found a dose-related rise in heart rate that peaked at 24 weeks and then declined.
In tirzepatide vs retatrutide, the key safety difference is not one number. Tirzepatide's safety profile is summarized in an FDA-reviewed label built on years of use. Retatrutide's is still being assembled from trials, and rare or long-term risks are by definition less well known for a drug that has not yet been used outside research. For more on that evidence, see our retatrutide dosing guide, which explains what the trial protocols can and cannot tell you.
Tirzepatide vs retatrutide dosing
Tirzepatide is injected under the skin once a week. Its label starts everyone at 2.5 mg a week for four weeks, then raises the dose in 2.5 mg steps at least four weeks apart, to a maintenance dose of 5, 10 or 15 mg. The starting dose is not meant for weight maintenance; it exists to let the body adjust.
Retatrutide has no approved dose. The trials gave it as a weekly injection at fixed research doses, raised in steps, under close medical follow-up. Those protocols describe what happened to volunteers in a study. They are not instructions, and copying a dose from a trial table onto a product bought online combines an unknown substance with an untested routine.
Tirzepatide vs retatrutide cost
On price, tirzepatide vs retatrutide is not a contest between two offers. Tirzepatide's price is public. Paying cash through Lilly, Zepbound costs:
| Zepbound strength | Lilly self-pay price per month |
|---|---|
| 2.5 mg starting dose | $299 |
| 5 mg | $399 |
| 7.5 mg to 15 mg, refilled within 45 days | $449 |
Lilly defines a month as 28 days for these prices. With commercial insurance that covers Zepbound, the savings card can bring the cost down to as little as $25, and eligible Medicare beneficiaries can get the Zepbound KwikPen through the Medicare GLP-1 Bridge for $50 a month. Our tirzepatide cost guide explains the conditions behind each figure, including what happens if a refill is late.
Retatrutide has no legal price, because it is not on sale. Any figure you see quoted online is the price of an unapproved product from an unverified source. A low price there is not a bargain; it is a sign that nothing about the contents has been checked.
What should you do if you want retatrutide?
If retatrutide's trial results interest you, there are two legitimate paths.
- Ask about clinical trials. Studies are listed on ClinicalTrials.gov, with their locations and eligibility rules. A trial provides the drug under medical supervision, with monitoring the study requires.
- Talk to a clinician about the approved options. Tirzepatide and semaglutide are both approved for weight management and are available by prescription now. A clinician can weigh your health history against each label.
What to avoid is buying a vial labeled retatrutide from a website, a social media seller or a "research peptide" shop. The FDA's warning applies directly, and a product you cannot verify cannot be dosed safely. Our safety guide covers how to tell a licensed pharmacy from an unregulated seller.
Where to get tirzepatide legally
Tirzepatide for weight management is sold as Zepbound and prescribed by your own doctor or by licensed telehealth clinics. Start with our tirzepatide hub, which lists the online clinics that prescribe it, each with its price and a link to its full review. The Zepbound insurance and self-pay guide covers the payment routes, and how to get Zepbound without insurance walks through the steps.
Tirzepatide vs retatrutide FAQ
Is retatrutide stronger than tirzepatide? Its trials reported larger average weight loss, 25.0% at the highest dose over 80 weeks against 20.9% for tirzepatide over 72 weeks. Those were separate placebo-controlled trials with different lengths and volunteers, so they do not prove one drug is stronger for any individual.
Can I switch from tirzepatide to retatrutide? Not legally outside a clinical trial, because retatrutide is not FDA approved. Stopping an approved medicine to take an unapproved product replaces a known treatment with an unknown one.
Is compounded retatrutide legal? No. The FDA states that retatrutide cannot be used in compounding under federal law. A product described as compounded retatrutide is not an approved or lawfully compounded medicine.
When will retatrutide be available? Only after the FDA approves it, and no approval has been granted as of October 18, 2026. Until there is an approved label, there is no legitimate prescription route.
Is tirzepatide the same as Zepbound? Yes. Zepbound is the brand name of tirzepatide approved for weight management. Mounjaro is the same molecule approved for type 2 diabetes.
Related reading
- Tirzepatide clinic hub
- Retatrutide dosing: what the trials can and cannot tell you
- Tirzepatide cost per month
- Semaglutide vs tirzepatide
- Zepbound insurance coverage and costs without insurance
Medical disclaimer: This page is for information only and is not medical advice. Talk to a licensed clinician before starting, stopping or changing any medication.
About this page: It carries no clinic recommendations and no affiliate links. See our editorial policy for how we source health information.
Sources: the Zepbound prescribing information on DailyMed, revised August 2026, read October 18, 2026; TRIUMPH-1, New England Journal of Medicine, September 29, 2026; TRIUMPH-2, The Lancet, October 10, 2026; the retatrutide phase 2 trial, New England Journal of Medicine, August 10, 2023; the FDA's page on unapproved GLP-1 drugs used for weight loss, read October 18, 2026; Lilly's Zepbound self-pay, savings card and Medicare Bridge prices, read October 12, 2026.